| Literature DB >> 28205624 |
Tibor Kovács1,2, Viktor Billes1, Marcell Komlós1, Bernadette Hotzi1,2, Anna Manzéger2, Anna Tarnóci1, Diána Papp1, Fanni Szikszai2, Janka Szinyákovics2, Ákos Rácz3, Béla Noszál3, Szilvia Veszelka4, Fruzsina R Walter4, Mária A Deli4, Laszlo Hackler5, Robert Alfoldi5, Orsolya Huzian5, Laszlo G Puskas5, Hanna Liliom6, Krisztián Tárnok6, Katalin Schlett6,7, Adrienn Borsy8, Ervin Welker8, Attila L Kovács9, Zsolt Pádár1, Attila Erdős1, Adam Legradi10, Annamaria Bjelik10, Károly Gulya10, Balázs Gulyás11,12,13, Tibor Vellai1,2.
Abstract
Autophagy functions as a main route for the degradation of superfluous and damaged constituents of the cytoplasm. Defects in autophagy are implicated in the development of various age-dependent degenerative disorders such as cancer, neurodegeneration and tissue atrophy, and in accelerated aging. To promote basal levels of the process in pathological settings, we previously screened a small molecule library for novel autophagy-enhancing factors that inhibit the myotubularin-related phosphatase MTMR14/Jumpy, a negative regulator of autophagic membrane formation. Here we identify AUTEN-99 (autophagy enhancer-99), which activates autophagy in cell cultures and animal models. AUTEN-99 appears to effectively penetrate through the blood-brain barrier, and impedes the progression of neurodegenerative symptoms in Drosophila models of Parkinson's and Huntington's diseases. Furthermore, the molecule increases the survival of isolated neurons under normal and oxidative stress-induced conditions. Thus, AUTEN-99 serves as a potent neuroprotective drug candidate for preventing and treating diverse neurodegenerative pathologies, and may promote healthy aging.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28205624 PMCID: PMC5311965 DOI: 10.1038/srep42014
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379